However, Chen and colleagues demonstrated that modest overexpression of AR also results in less specific ligand recognition on prostate cancer [40], indicating AWS can be expected in more cases with disease progression against anti-androgen administration. The gene discussed is AR; the disease is Familial prostate cancer.